NCT06920238 Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
| NCT ID | NCT06920238 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Trustees of Dartmouth College |
| Condition | Cannabis Use Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-04-13 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 15 participants in total. It began in 2025-04-13 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if Therabot-CALM (Cannabis, Anxiety, Low Mood) has acceptability among users and could work to improve the symptoms of persons with cannabis use disorder and anxiety and/or depression. The main question it aims to answer is: What is the usability, feasibility, and acceptability of Therabot-CALM in persons with Cannabis Use Disorder and Anxiety and/or Depression? Participants will * Take a screening questionnaire * Participate in two virtual 1-hour interviews to provide feedback on app design and suggest features. * Engage with Therabot-CALM in a 4-week clinical trial and provide feedback on their app experience in a third virtual interview
Eligibility Criteria
Inclusion Criteria: * Is 18 years or older. * Meet criteria for current CUD (CUDIT-R\>=12) and MDD (PHQ-9\>=10), and/or GAD (GAD-7\>=10). * Have reliable access to the internet and a compatible device for Therabot-CALM. * Have willingness and capacity to provide informed consent and commit to participating in all assessments and interventions during the study. * Attend the first interview. Exclusion Criteria: * Moderate to High risk of STBs as determined by the C-SSRS or baseline questionnaires. * Current psychosis (as determined by brief psychosis screen). * Current participation in another digital mental health intervention.
Contact & Investigator
Nicholas C Jacobson, Ph.D.
PRINCIPAL INVESTIGATOR
Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College
Frequently Asked Questions
Who can join the NCT06920238 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cannabis Use Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06920238 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06920238 currently recruiting?
Yes, NCT06920238 is actively recruiting participants. Contact the research team at michael.v.heinz@hitchcock.org for enrollment information.
Where is the NCT06920238 trial being conducted?
This trial is being conducted at Lebanon, United States.
Who is sponsoring the NCT06920238 clinical trial?
NCT06920238 is sponsored by Trustees of Dartmouth College. The principal investigator is Nicholas C Jacobson, Ph.D. at Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College. The trial plans to enroll 15 participants.